在高风险的肺动脉栓塞中使用不同的导管干预治疗方法的临床结果
Luise Antonia Mentzel1, Parham Shahidi1, Stephan Blazek1
1Department of Cardiology, Heart Center Leipzig at University of Leipzig, Struempellstr. 39, 04289 Leipzig, Germany.
Journal of cardiovascular development and disease
|July 26, 2024
概括
大孔血栓切除可能会降低高风险肺动脉栓塞 (PE) 患者的死亡率. 这项研究表明它是.
科学领域:
- 干预心脏病学 干预心脏病学
- 肺部医学 肺部医学
- 血管外科 血管外科
背景情况:
- 高风险的肺动脉栓塞 (PE) 需要除了抗凝药之外的高级治疗.
- 导管导向治疗正在成为PE的有效选择.
- 对于高风险PE的导管干预存在有限的比较数据.
研究的目的:
- 为了比较大孔导管血栓切除术与高风险PE的替代导管干预的疗效.
- 评估与严重PE不同导管治疗相关的死亡率.
主要方法:
- 回顾性,单中心研究设计.
- 包括20名患有高风险PE的患者进行了导管干预.
- 大孔血栓切除术与替代性干预治疗之间的结果比较.
主要成果:
- 大孔血栓切除术 (9名患者) 与替代方案 (11名患者) 相比,显示了较低周围手术死亡率的趋势 (0%对55%).
- 大孔血栓切除术的住院死亡率明显较低 (33%对82%,p=0.01).
- 基线特征在各组之间相似,表明治疗是区分因素.
结论:
- 大孔血栓切除似乎与高风险PE患者的死亡率降低有关.
- 需要进一步的前性研究来证实这些发现.
- 导管血栓切除术代表了严重肺栓塞的有前途的治疗策略.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
152
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
152
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
149
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
149
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
165
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
165
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
192
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
192
Flail Chest-II
160
Managing flail chest, a condition characterized by a segment of the chest wall moving independently from the rest of the thoracic cage, requires a comprehensive approach. It includes a thorough assessment of the patient's condition, a diagnostic evaluation to determine the extent of the injury, and the implementation of appropriate medical interventions tailored to the individual's needs.
Assessment:
1. Clinical Evaluation:
History:
Assessment:
1. Clinical Evaluation:
History:
160


